Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 378 participants.
Also called NCT01932112
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 378 participants
- Sponsor
- Yong Seog Oh
- Registry
-
NCT01932112
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01932112. Allocation not applicable; no masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2015-04 (actual). Results posted on 2016-04-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)
- Acronym
- APPLE
- Condition
- Atrial Fibrillation
- Condition
- Persistent Common Pulmonary Vein
- Intervention (Drug)
- Adenosine arm
- Lead sponsor
- Yong Seog Oh
Record details
- Record id
cardio:ct-nct01932112- Content hash
0e99e4f0febedfaf031f30f1b516db1c2ec1b0042b02ea0f41766bef299693b7